V-HEFT

V-HEFT

Cardiology A trial–Veterans Heart Failure Trial that evaluated the effect of combination vasodilator–hydralazine and isosorbide dinitrate therapy in Pts with severe heart failure. See ACE inhibitor, Congestive heart failure, Enalapril, Hydralazine-isosorbide dinitrate, NY Heart Association classification.
References in periodicals archive ?
A-HeFT, V-HeFT 1 and V-HeFT 2 have evaluated the benefits of H + ISDN in various groups and in different comparisons.
The results of the first clinical trial, called the Vasodilator Heart Failure Trial (V-HeFT I), were deemed unconvincing by the relevant regulatory body, the US Food and Drug Administration's (FDA) Cardiovascular and Renal Drug Advisory Committee.
A study comparing the formulations of isosorbide dinitrate (ISDN) and hydralazine (HYD) used in V-HeFT I and V-HeFT II, and BiDil, the proprietary fixed dose combination, used in the African American Heart Failure Trial (A-HeFT) demonstrated no bioequivalence.
The Vasodilator-Heart Failure Trial (V-HeFT) demonstrated that nitrates in combination with hydralazine are not as effective as ACE inhibitors, yet they are better than placebo.
Cohn, M.D., was principal investigator of V-HeFT I, which compared the drug combination with placebo added to standard therapy in the early 1980s in male patients with mild HF, and a few years later.
The findings confirmed the hypotheses generated from V-HeFT I and II, said Clyde Yancy, M.D., medical director of the Heart Failure/Transplantation Program at the University of Texas Southwestern Medical School, Dallas, speaking for NitroMed.
For example, the Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trial (V-HEFT II) utilized the Minnesota 'Living with Heart Failure Questionnaire' to assess outcomes in patients randomized to either enalapril or hydralazine plus isosorbe dinitrate.
This finding echoes that of the V-HeFT II trial, which used illness-specific measures of health status to evaluate outcomes of treatment.
Cohn, M.D., was the principal investigator in V-HeFT I, which compared the drug combination with placebo added to standard therapy in the early 1980s in male patients with mild HE and a few years later, V-HEFT II, which compared the combination with enalapril, added to standard therapy.
The study results confirmed the hypotheses generated from V-HeFT I and II, said Clyde Yancy, M.D., medical director of the Heart Failure/Transplantation Program at the University of Texas Southwestern Medical School, Dallas, speaking for NitroMed at the panel meeting.
"The V-HeFT I results were similar, even though most of those patients were not African Americans.
Cohn during the early 1980s, the first Veterans Affairs Vasodilator Heart Failure Trial (V-HeFT I).